
    
      Upon determination of eligibility, patients will be receive:

      Oxaliplatin + Docetaxel + Capecitabine + Radiation therapy

      If the three-drug chemotherapy regimen, with radiation therapy, is tolerable, this regimen
      will be taken forward into the phase II portion of the trial. If the three-drug regimen is
      too toxic, the phase II portion will proceed with the two-drug regimen Oxaliplatin +
      Docetaxel + Radiation therapy
    
  